10-Q quarterly report · filed Nov 5, 2026

Entrada Therapeutics, Inc. (TRDA) Q3 2026 10-Q Quarterly Report

Short answer

Entrada Therapeutics, Inc. (TRDA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $905,000 (down 43.9% year over year) with net income of −$40M.

Q3 2026 key financials · XBRL

Revenue
$905,000
−43.9% YoY · +0.8% QoQ
Net income
−$40M
+10.0% YoY · +7.1% QoQ
Operating margin
-4606.5%
EPS (diluted)
−$0.94
+11.3% YoY · +6.9% QoQ

Source: XBRL data from the Entrada Therapeutics, Inc. (TRDA) Q3 2026 10-Q on SEC EDGAR. USD.

Entrada Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Collaboration revenue $0.9M, down $0.7M YoY from $1.6M
  • Net loss $39.7M vs $44.1M YoY, operating loss $41.7M vs $47.1M
  • ENTR-601-44 highest program spend at $6.2M, ENTR-601-45 increased to $4.5M
  • Operating cash use $104.1M, marketable-securities maturities drove $124.9M investing inflow
  • Cash, equivalents and securities $193.0M, funding expected into fourth quarter 2027; additional funding required

Risk Factors

  • Newly added regulatory risk: October 2026 FDA orphan-drug designation for ENTR-601-45 may not deliver exclusivity or other benefits
  • Most material regulatory update: June 2026 FDA draft guidance permits one pivotal trial with confirmatory evidence, but additional trials remain possible
  • Compliance risk: BIOSECURE Act Section 851 could disrupt China-based suppliers and foreign contract manufacturers
  • Operational risk: Vertex controls VX-670 development, with interim GALILEO Phase 1/2 results expected in second half of 2026
  • Financial risk: Cash, equivalents and marketable securities fund operations into fourth quarter 2027, but substantial going-concern doubt remains

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Entrada Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.